Category: Health News

Leading podiatrist in Wayne, New Jersey, partners with the Ankle & Foot Centers of America, the nation’s leading group of foot and ankle surgeons. This relationship allows doctors to dedicate their time to treating patients instead of administrating a podiatry practice.

Lindsey Calligaro, DPM

WAYNE, N.J. – November 1, 2022 – (Newswire.com)

Renown New Jersey podiatrist Lindsey Calligaro, DPM, of Wayne Foot & Ankle Center has recently teamed with Ankle & Foot Centers of America, the market leader in physician practice management and process improvement, to better serve patients. Wayne Foot & Ankle Center has been providing the highest-quality care to patients for over 40 years, and is dedicated to improving the lives of people in the northern NJ community.

Dr. Lindsey Calligaro earned her Doctor of Podiatric Medicine from the New York College of Podiatric Medicine in 2011 and attended a comprehensive three (3) year residency in Scranton, Pennsylvania with Dr. Guido LaPorta. Dr. Calligaro served as Chief Fellow during her fellowship in Baltimore, Maryland, at the Rubin Institute for Advanced Orthopedics/International Center for Limb Lengthening. Dr. Calligaro’s training specialized in complex foot and ankle deformity correction and pediatric deformity correction. Dr. Calligaro treats a variety of foot and ankle problems, including bunions, heel pain, trauma, and flatfeet. She also specializes in all aspects of pediatric foot and ankle deformity correction with a special interest in clubfoot. Helping to serve the needs of patients is what brought Dr. Calligaro to podiatry, and it is what motivates her to provide the best care possible every day.

Teaming with Ankle & Foot Centers of America allows physicians like Dr. Calligaro to do what they do best, take care of patients. With Ankle and Foot Centers of America, Dr. Calligaro is now able to benefit from the most advanced software, reporting, and office support in the industry. As healthcare becomes more complicated with technology and regulation, physicians must rely on expert support.

Incorporating the central scheduling team and call center from Ankle and Foot Centers of America allows patients to make appointments with greater ease with this Wayne, NJ, Podiatrist. Whether booking online or over the phone, patients can now expect to have a more streamlined experience. Additionally, Ankle and Foot Centers of America incorporates advanced network safeguards to better protect patient data and provides new training for staff on the latest advances and changes in healthcare.

With a shared commitment to excellence and dedication to patient well-being, Dr. Calligaro and the team at Ankle and Foot Centers of America look forward to treating the foot and ankle needs of patients in north New Jersey.

About Ankle & Foot Centers of America – Founded in Atlanta over 30 years ago, Ankle & Foot Centers of America is dedicated to providing patients with top-tier service and support through best-in-class technology and processes so that physicians can optimize patient outcomes and satisfaction.

Contact Information:

Alexis Pickford

Marketing Representative

678-561-9000

Press Release Service
by
Newswire.com

Original Source:

New Jersey Podiatrist Teams with Ankle & Foot Centers of America

The post New Jersey Podiatrist Teams with Ankle & Foot Centers of America first appeared on Enrose Magazine.

As published in the journal Food and Chemical Toxicology, the biopharmaceutical drug development firm’s sponsored research used co-cultured human, primary immune cells as a model to evaluate the ability of selected Cannabis constituents to decrease inflammation.

Gb Sciences

LAS VEGAS – November 1, 2022 – (Newswire.com)

Gb Sciences, Inc. (OTCQB:GBLX), a leading plant-inspired, biopharmaceutical research and drug development company, has co-published a study in the journal Food and Chemical Toxicology that demonstrates the potential of selected cannabinoids and terpenes to reduce inflammation. Finding Cannabis compounds with anti-inflammatory properties may be useful in decreasing inflammation associated with a wide range of serious human disorders, and these Cannabis compounds potentially have more favorable side effect profiles than NSAIDs (Non-Steroidal Anti-Inflammatory Drugs), which currently lead the anti-inflammatory market based on sales. Largely because of the increasing prevalence of chronic and auto-immune inflammatory disorders, the market for anti-inflammatory therapies is expected to grow to $191.42 billion by 2027.

“We believe that this is the first demonstration of the anti-inflammatory potential of some very potent minor cannabinoids and terpenes derived from Cannabis,” said Dr. Andrea Small-Howard, President, Chief Science Officer, and Director of Gb Sciences. “The identification of cell type-specific immune modulating effects by different individual cannabinoids and terpenes was an important first step in designing our novel anti-inflammatory therapies. The results from our second study on the anti-inflammatory effects of proprietary mixtures of these ingredients will be published subsequently with our collaborators at Michigan State University and Chaminade University.”

Gb Sciences selected the specific Cannabis constituents for this study based on their prior activity within chemovar studies. To determine whether these cannabinoids and terpenes could reduce inflammation, Gb Sciences’ colleagues at Michigan State University tested the individual Cannabis constituents over a wide range of concentrations in human, primary immune cells in a co-culture system that mimics the complex interactions that regulate the human immune system. Three immune cell types were chosen as representatives within these native human immune cell mixtures based on their important roles in modulating the inflammatory cascade.

This study demonstrated that delta-9 tetrahydrocannabinol (THC) had the greatest effect on reducing inflammatory biomarkers and processes in all three immune cell types. Following THC, the greatest immune activity modulation was measured by cannabidivarin (CBDV), cannabigerol (CBG), cannabichromene (CBC), cannabinol (CBN), and lastly, cannabidiol (CBD) in decreasing order based on the number of statistically significant changes measured in inflammatory bioassays relative to the control. Some of these minor cannabinoids and the terpenes tested had very ‘selective’ anti-inflammatory effects, which targeted a single cell type and/or caused a change in only a single inflammatory bioassay.

This study entitled “Evaluation of the anti-inflammatory effects of selected cannabinoids and terpenes from Cannabis Sativa employing human primary leukocytes” was co-authored by Gb Sciences’ own President and Chief Science Officer, Andrea Small-Howard, and her collaborators Lance K. Blevins, Anthony P. Bach, Robert B. Crawford, Jiajun Zhou, Joseph E. Henriquez, Michael D. Rizzo, Sera Sermet, D.M. Isha Olive Khan, and Norbert Kaminski from Michigan State University (East Lansing, Michigan, USA) and Helen Turner from Chaminade University of Honolulu (Honolulu, Hawai’i, USA). The second part of this study measured the effects of proprietary mixtures of cannabinoids and terpenes on inflammation within this human, primary immune cell model, and this second study will be published next in collaboration with our colleagues at Michigan State University and Chaminade University.

To learn more about Gb Sciences, visit www.gbsciences.com.

About Gb Sciences and GbS Global Biopharma

Gb Sciences, Inc. is a plant-inspired, biopharmaceutical research and development company creating patented, disease-targeted formulations of cannabis- and other plant-inspired therapeutic mixtures for the prescription drug market through its Canadian subsidiary, GbS Global Biopharma, Inc. The ‘plant-inspired’ active ingredients in its therapeutic mixtures are synthetic homologues identical to the original plant compounds but produced under current Good Manufacturing Practices. Gb Sciences’ intellectual property portfolio contains six issued U.S. and three issued foreign patents, as well as 17 U.S. and 51 foreign patent-pending applications. In its drug development pipeline, Gb Sciences has five preclinical phase product development programs. Gb Sciences’ lead program for Parkinson’s disease is being prepared for a first-in-human clinical trial. Gb Sciences’ formulations for chronic pain, anxiety, and depression are currently in preclinical animal studies with researchers at the National Research Council of Canada. The company also received positive preclinical proof-of-concept data supporting its complex mixtures for the treatment of Cytokine Release Syndrome related to COVID-19, and its lead candidates will be optimized based on late-stage preclinical studies at Michigan State University. Gb Sciences’ productive research and development network includes distinguished universities, hospitals, and Contract Research Organizations. To learn more, visit www.gbsciences.com.

Forward-Looking Statements

This press release may contain statements relating to future results or events, which are forward-looking statements. Words such as “expects”, “intends”, “plans”, “may”, “could”, “should”, “anticipates”, “likely”, “believes” and words of similar import may identify forward-looking statements. These statements are not historical facts, but instead represent only the Company’s belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company’s control. It is possible that the Company’s actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Further, information concerning the Company and its business, including factors that potentially could materially affect the Company’s business and financial and other results, are contained in the Company’s filings with the Securities and Exchange Commission, available at www.sec.gov. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.

Contact Information:

Madeleine Moench

madeleine@newswire.com

Press Release Service
by
Newswire.com

Original Source:

Gb Sciences Co-Publishes Study Demonstrating Anti-Inflammatory Properties of Cannabis Ingredients

The post Gb Sciences Co-Publishes Study Demonstrating Anti-Inflammatory Properties of Cannabis Ingredients first appeared on Enrose Magazine.

i am the queen of new york im a new york native new york is all ive ever known its in my blood i directed the cheetah girls thanks @lastmanstanley for editing my videos you old scally wag Vogue please dont be mad at me ive wanted to do this video for so long and […]

CARY, N.C. – November 1, 2022 – (Newswire.com)

InstantGMP, the originators of the all-in-one manufacturing and quality system, is proud to welcome a new contract development and manufacturing organization, Quality Chemical Laboratories (QCL), to its growing client base.

Quality Chemical Laboratories was founded in 1998 as a raw material testing laboratory and has continuously expanded capabilities and service offerings. For over 25 years, this leading CDMO has provided GMP-compliant formulation development and manufacturing services for the pharmaceutical industry. The company’s clients range from small start-up companies to some of the most prominent pharmaceutical corporations in the world.

As its client base continues to grow, Quality Chemical Laboratories recognized the importance of implementing a new software system to enhance its processes while gaining efficiency and maintaining GMP and FDA compliance.

QCL’s exhaustive search for a new software system led the company to the InstantGMP PRO system. While the software’s all-in-one capabilities impressed the QCL team, they required computer system validation to determine if the system:

• Meets FDA Part 11 compliance.
• Achieves its intended purpose by meeting user requirements.
• Is free from any installation or performance issues that could negatively impact the integrity of the CDMO’s production cycles, raw materials or finished pharmaceutical products.

To ensure that the InstantGMP PRO system was validated, Quality Chemical Laboratories conducted an extensive software vendor audit. During the software vendor auditing process, QCL reviewed every piece of the software’s validation documentation and standard operating procedures (SOPs) via a virtual session with InstantGMP to confirm that InstantGMP PRO:

• Is properly validated.
• Vendor documentation can be appropriately leveraged to save QCL significant time and resources.
• Functions accordingly and accurately.
• Aligns with the information defined in the provided user requirement documentation.

After QCL reviewed all the respective documentation and asked any pertinent questions, it created and supplied a detailed audit report that identified topics that required further discussion and some minor issues that needed to be resolved. At the conclusion of the audit process, InstantGMP successfully satisfied Quality Chemical Laboratories’ requirements.

Not only did this process lead to a successful relationship, but it also provided the QCL team a better understanding of the software’s full capabilities. Additionally, the audit process offered InstantGMP an opportunity to address previously unidentified issues and further enhance the software with new features that best meet manufacturers’ needs.

InstantGMP is excited to provide Quality Chemical Laboratories with a validated all-in-one software system that truly meets its needs for improved processes and assured compliance. InstantGMP wishes them continued success in the contract formulation development and manufacturing industry and thanks them for helping InstantGMP enhance their software during the audit process.

To learn more about InstantGMP PRO‘s new features and software auditing processes for GMP manufacturers, contact us to schedule a demonstration.

Contact Information:

Robert Pochadt

Director of Sales

rpochadt@instantgmp.com

215-975-9660

Jeremy Hall

Technical Sales Manager

jhall@instantgmp.com

757-759-4500

Related Files
InstantGMP PRO for FDA Requlated Industries 4.22.pdf

Press Release Service
by
Newswire.com

Original Source:

New CDMO Client, Quality Chemical Laboratories, Benefits From InstantGMP’s All-in-One Quality & Manufacturing System and Software Auditing for GMP Manufacturers

The post New CDMO Client, Quality Chemical Laboratories, Benefits From InstantGMP’s All-in-One Quality & Manufacturing System and Software Auditing for GMP Manufacturers first appeared on Enrose Magazine.

ZetrOZ’s sam®️ technology promotes soft tissue healing, helping patients return to work sooner and preventing more severe injuries; the only FDA-cleared home-use multi-hour ultrasound stimulator.

ZetrOZ Systems

TRUMBULL, Conn. – October 31, 2022 – (Newswire.com)

ZetrOZ Systems presented to the Michigan Self-Insurers Association 2022 Fall Conference on Oct. 27 about how the ZetrOZ sam® wearable ultrasound device helps patients return to work more quickly after soft-tissue injuries and prevents more severe injuries from occurring. 

ZetrOZ Systems has partnered with the organization of self-insured employers on ways to educate businesses on how to prevent and respond to workplace accidents and injuries. The sam® device has been shown in more than 30 clinical studies to deliver significant improvement in joint function, increased pain reduction, and improved vasodilation – all of which ultimately contribute to accelerated healing and increasing integrity of recovered soft tissue. The sam® product line is also shown to mitigate pain from soft-tissue injuries in the upper neck and back, shoulder conditions, and knee osteoarthritis. 

“sam® is already helping thousands of lives daily, and we’re honored to be partnering alongside MSIA and the self-insured businesses in Michigan to provide effective treatment for workplace injuries,” said Dr. George Lewis, CEO of ZetrOZ Systems. “It’s incredibly important to us to help treat workers’ injuries, relieve pain, improve long-term outcomes, and ultimately, get people back to work sooner.”

Statistics show a need for better care for the workforce, particularly at self-insured workplaces. American workers experienced 2.1 million injuries in 2020, according to the U.S. Bureau of Labor Statistics, and 82% of workers at large firms were covered by self-funded insurance plans in 2021. 

There also is a need for effective pain relief without potentially addictive and dangerous medications. The United States spends about $1 trillion on opioid use disorder and fatal opioid overdoses (2018, Centers for Disease Control and Council of Economic Advisors). Innovations like the sam®x1  pain relief ultrasound device provide wireless, long-duration ultrasound therapy for injury healing and pain relief without medication.

The Michigan Self-Insurers’ Association [MSIA] is a non-profit organization founded in 1952 that has worked tirelessly over the last 70 years to educate self-insured employers on workers’ compensation issues. With the goal of reducing and ultimately preventing workplace accidents and injuries, MSIA and sam® are uniquely aligned to empower workers with the tools and resources to protect themselves and their livelihoods. 

MSIA’s Board of Managers includes DTE, Meijer, Marathon Oil, and representation from many other self-insured employers, and the organization has been a proud partner of Kids’ Chance of Michigan since 2013.

“Our sam® product portfolio offers patients a way to mitigate and reduce workplace injury and pain without resorting to opioids or nonsteroidal anti-inflammatory drugs, which have shown to potentially harm more than they help. Now, these hard-working men and women have a chance to safely and properly heal in the comfort of their own homes,” Lewis said. 

To learn more, visit zetrozsystems.com.  

About ZetrOZ Systems

ZetrOZ Systems is leading healing innovations in sports medicine and developing wearable bioelectronic devices for the delivery of sustained acoustic medicine (sam®). Researched and funded by the federal government, ZetrOZ is built on proprietary medical technology of +46 patents and is the exclusive manufacturer and developer of sam®, a product line designed for the treatment of acute and chronic musculoskeletal conditions. To learn more, visit zetrozsystems.com.

Contact Information:

Buse Kayar

buse@newswire.com

Press Release Service
by
Newswire.com

Original Source:

ZetrOZ Partners With Michigan Self-Insurers Association to Educate on Sustained Acoustic Medicine for Workplace Injury Healing

The post ZetrOZ Partners With Michigan Self-Insurers Association to Educate on Sustained Acoustic Medicine for Workplace Injury Healing first appeared on Enrose Magazine.

Produced by Vogue with Kate Somerville She swears by this cult-favorite brand’s exfoliants, eye cream, and moisturizer. Shop this beauty routine: ExfoliKate Intensive Treatment: ExfoliKate Body Scrub: KateCeuticals Lifting Eye Cream: KateCeuticals Total Repair Cream: Still haven’t subscribed to Vogue on YouTube? ►► Get the best of Vogue delivered right in your inbox ►► Want […]

Fusion Marketplace is taking every step possible to make sure healthcare professionals feel supported while they navigate their careers.

Fusion Mar…

The post Healthcare Job Platform Cultivates Support and Conversation Among Travel Healthcare Professionals first appeared on Enrose Magazine.

The Richard N. Merkin Prize in Biomedical Technology
CAMBRIDGE, Mass. – October 31, 2022 – (Newswire.com)
…

The post Launch of the Merkin Prize in Biomedical Technology first appeared on Enrose Magazine.

► Subscribe to Sky Sports News: Assessing the job in hand for Graham Potter at Chelsea. #SkySportsNews #SkySports

PolarSeal Tapes and Conversions, a leading medical converting specialist, has announced its new order-tracking system for the medical device industry.

…

The post PolarSeal Announces Launch of Their New Innovative Order-Tracking Platform for the Medical Device Industry first appeared on Enrose Magazine.